Kristen Williams, Chief Administrative Officer of Pacira BioSciences, Inc. (NASDAQ:PCRX), completed two separate dispositions of company stock at the end of January and the start of February 2026.
On February 2, 2026, Williams sold 13,137 shares of Pacira common stock at a per-share price of $20.53, a transaction that totaled approximately $269,702. A few days earlier, on January 30, 2026, she disposed of 17,134 shares at $20.54 per share, a sale valued at $351,932. The January transaction was carried out to cover tax withholding obligations tied to the vesting of a restricted stock unit award.
Following those sales, Williams retains direct ownership of 131,303 Pacira shares. Company filings indicate that the February sale was executed pursuant to a Rule 10b5-1 trading plan.
Beyond the insider transactions, Pacira reported several corporate and commercial developments. The company recorded total revenue of $726.4 million for 2025, a year-over-year rise from $701.0 million in 2024. Management attributed the increase largely to the performance of its EXPAREL product.
Pacira said fourth-quarter net product sales of EXPAREL amounted to $155.8 million, representing a 7% volume increase compared with the same quarter in 2024. In addition, the company announced an exclusive distribution agreement with LG Chem covering EXPAREL in select Asia-Pacific markets. Under the terms disclosed, LG Chem will be responsible for commercialization in those territories while Pacira will receive upfront payments and royalties.
On the governance front, Pacira added Samit Hirawat to its Board of Directors, bringing the board to 10 members. At the same time, activist investor DOMA Perpetual Capital Management LLC, which holds a 6.83% stake in Pacira, has said it plans to nominate three directors to the board and is advocating for the sale of the company.
Pacira also reported clinical progress: the company announced positive results from a pilot study indicating that its iovera° treatment provided better outcomes than radiofrequency ablation for chronic low back pain.
Taken together, the insider sales, financial results, distribution arrangement, board changes and activist investor activity mark a busy stretch for Pacira as it balances commercialization efforts, corporate governance developments and clinical data disclosure.